OneSource's Partner Dr. Reddy's Gains Health Canada Approval for Generic Semaglutide Injection
OneSource Specialty Pharma Limited announced that its partner, Dr. Reddy's Laboratories Ltd., has received a Notice of Compliance from Health Canada for Semaglutide Injection. The approval targets Semaglutide Injection, which is a generic version of Ozempic®.OneSource Specialty Pharma Limited stated that it serves as the CDMO partner for this program, providing scale-up and manufacturing support. The partnership is strategically positioned to ensure a reliable and scalable commercial supply utilizing OneSource's US-FDA approved flagship manufacturing facility located in Bengaluru.
Neeraj Sharma, CEO & MD of OneSource Specialty Pharma Limited, commented on the development. He stated, "We are pleased to announce that our partner Dr. Reddy's has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy's expertise in peptide development with OneSource's CDMO capabilities."
About OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is defined as a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products across several categories, including biologics, drug-device combinations, sterile injectables, and oral technologies such as soft gelatine capsules.The company operates five state-of-the-art manufacturing facilities that are approved by global regulatory authorities. OneSource maintains a dedicated team comprising over 1,600 professionals. Leveraging its development capabilities, industry leading manufacturing capacities, and strong compliance track record, the organization aims to provide global pharmaceutical companies with efficient, end-to-end solutions.
ONESOURCE Stock Price Movement
Shares of Onesource Specialty Pharma Limited are edging higher to ₹1819.7 as of 9:34 AM today, rallying a strong 3.22% in live trading on a ₹56.70 gain. The stock has seen significant momentum in the market, drawing an impressive volume of 117,188 shares in the session so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.